Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The past, present, and the future of disc nucleus replacement. A systematic review of a large diversity of ideas and experiences.
Biomaterials
January 2025
Institute of Orthopaedic Research and Biomechanics, Trauma Research Centre Ulm, Ulm University, Helmholtzstrabe 14, Ulm 89081, Germany; University of Palermo, Department of Engineering, Viale delle Scienze, 90128 Palermo, Italy.
Disc nucleus replacement (NR) is a challenging surgical technique used as a medical treatment for early-stage disc herniation to restore disc height and the biomechanical function of a motion segment, which may reduce low back pain. The surgical procedure involves the removal and replacement of the degenerated nucleus pulposus with a substitute by accessing the annulus fibrosos via a created hole. Over the decades, nucleus replacement has been an important issue, leading to the development of different substitute alternatives.
View Article and Find Full Text PDFRisk of ocular adverse events with aromatase inhibitors.
Can J Ophthalmol
October 2024
Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC.. Electronic address:
Objective: Aromatase inhibitors (AIs) are a class of medications used for adjuvant treatment of breast cancer. Recent case reports suggest that AIs may be associated with various ocular adverse events (AEs). This study evaluates the risk of ocular AEs in patients who take AIs.
View Article and Find Full Text PDFThe Effectiveness of Imipenem-Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase.
Antibiotics (Basel)
May 2023
Research Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, OH 44106, USA.
Background: Ceftazidime-avibactam was approved by the FDA to treat infections caused by Enterobacterales carrying . However, variants of KPC-2 with amino acid substitutions at position 179 have emerged and confer resistance to ceftazidime-avibactam.
Methods: The activity of imipenem-relebactam was assessed against a panel of 19 KPC-2 D179 variants.
Concise nanotherapeutic modality for cancer involving graphene oxide dots in conjunction with ascorbic acid.
Nanoscale
June 2023
Department of Chemical Engineering, National Cheng Kung University, Tainan 70101, Taiwan.
Article Synopsis
- Cancer cells have higher levels of reactive oxygen species (ROS) and are more susceptible to therapies that generate ROS, like ascorbic acid (HAsc), but effectiveness is limited by the need for high doses.
- The study introduces nitrogen-doped graphene oxide dots (NGODs) as a biocompatible catalyst that enhances HAsc therapy at manageable concentrations by generating additional ROS and depleting intracellular glutathione (GSH), which contributes to cancer cell damage.
- NGODs can also function as photosensitizers in photodynamic therapy, producing ROS when illuminated, leading to a promising new treatment that combines NGODs and HAsc for more effective tumor destruction while maintaining a high survival rate of normal cells.
Cohort-based learning for microbiome research community standards.
Nat Microbiol
May 2023
Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!